{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "IMRX",
  "name": "Immuneering Corporation",
  "url": "https://frontierpicks.com/dossiers/IMRX/",
  "json_url": "https://frontierpicks.com/dossiers/IMRX.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Busted-catalyst pancreatic biotech: atebimetinib's 17.3-mo single-arm 1L OS is real, but the Phase 3 binary is mid-2028 and the tape keeps fading post-ASCO ($5.11→$4.32 in two weeks) even as targets climb to $18–$30. Cheap value-optionality (~$80M EV vs $198.6M cash) with no dated OS catalyst for ~2 years — a base-building watch, not fresh momentum.",
  "invalidation_trigger": "A weekly close below $3.90 undercuts the post-ASCO base and confirms the market de-rating atebimetinib's single-arm OS toward the $2.90 52-week low; a competing MEK/MAPK Phase 3 miss or a dilutive raise into the Aug 12 print compounds the break.",
  "catalyst_date": null,
  "outcome": "PLAYED_OUT",
  "outcome_date": "2026-08-11",
  "invalidation_fired": false,
  "themes": [
    "oncology-immunology",
    "m-and-a-special-situations",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Clinical-stage, no approved products and no product revenue: valuation rests entirely on atebimetinib and the mid-2028 MAPKeeper 301 topline.",
    "The 17.3-month median OS is single-arm versus historical control; no randomized comparator data exists before mid-2028.",
    "Cash runway 'into 2029' is company guidance from the 2026-08-05 Q2 release, not a financing commitment.",
    "CFO Andrew Gengos took the role effective 2026-07-16.",
    "64.7M weighted-average shares outstanding (Q2 2026) — a thin structure that gaps in both directions on single headlines."
  ],
  "body_markdown": "## Current Thesis\nThe prior read on Immuneering was a busted-catalyst pancreatic name bleeding out of ASCO while sell-side targets climbed. Three weeks on, the bleed stopped. Price closed $4.32 on July 24, 2026 and $5.06 on August 14, 2026; the Q2 print on August 5 showed $182.7M in cash, cash equivalents and marketable securities at June 30, 2026 (down from $217.0M at year-end 2025) with runway guidance into 2029 and no financing announced alongside it; HC Wainwright initiated with a Buy and a $14 target on August 6. What has not changed is the shape of the story: the 17.3-month median overall survival from the single-arm Phase 2a is a historical-control comparison, and the randomized readout that confirms or kills it — MAPKeeper 301 topline, primary endpoint OS — is guided to mid-2028. The narrative leg an investor buys here is a cash-covered option on that 2028 print, priced at a $5.06 reference close against $182.7M of cash and 64.7M weighted-average shares, with four brokers now published between $14 and $30. The leg an investor is not buying is a dated near-term event, because there isn't one.\n\n## Bull Case\n- Q2 2026 (reported August 5, 2026): $182.7M cash, cash equivalents and marketable securities at June 30, 2026, with stated runway into 2029 — i.e. funded through the mid-2028 Phase 3 topline without a required raise on the company's own guidance.\n- Phase 2a atebimetinib + modified gemcitabine/nab-paclitaxel: 17.3-month median OS and 64% 12-month OS in 55 first-line metastatic pancreatic patients, plus 84% of evaluable patients weight-stable or gaining at 3 months (ASCO oral presentation, June 1, 2026). The tolerability/weight datapoint matters in an indication where cachexia drives dropout.\n- Coverage has widened four times in five weeks against a falling-then-recovering tape: Cantor Fitzgerald Overweight initiation July 8, 2026; Needham Buy with target raised $11→$18 on July 20, 2026; HC Wainwright Buy initiation with a $14 target on August 6, 2026; Oppenheimer Outperform at $30. Every published target sits multiples above the August 14 close of $5.06.\n- MAPKeeper 301 is executing, not just announced: first patient dosed June 11, 2026; over 30 study locations posted to clinicaltrials.gov as of the August 5, 2026 update. Slow site activation is the usual first crack in a small-cap pivotal; it has not appeared yet.\n- Second shot on goal with a dated path: NSCLC Phase 2 of atebimetinib + Regeneron's cemiplimab expected to dose its first patient in 2H 2026, preclinical combination data in Q4 2026, preliminary clinical data late-2027 — a readout that arrives roughly a year before the pancreatic binary.\n\n## Bear Case\n- The 17.3-month figure is single-arm versus historical control. Pancreatic cross-trial comparisons have a long record of not surviving randomization, and no comparator arm exists until mid-2028.\n- Burn is accelerating into the Phase 3: Q2 2026 R&D $14.0M versus $10.5M in Q2 2025, G&A $5.0M versus $4.3M, net loss $17.3M / $(0.27) per share. A 510-patient global trial does not get cheaper from here, and \"into 2029\" is a guidance statement, not a covenant.\n- Price remains 45.4% below the $9.26 52-week high on the adjusted series as of August 14, 2026, and the 3-month return is -1.9%. The recovery off July has restored a base, not a trend that has proven itself against the highs.\n- The gap between a $5.06 close and a $14–$30 published target range has persisted through four broker actions since July 8. When targets move and price does not follow for weeks, the marginal buyer is being described rather than observed.\n- Between now and late-2027 NSCLC prelim data, the flow of hard clinical information is close to zero. Attention decay in a 64.7M-share biotech with no revenue is the default state, not a risk case.\n\n## Setup & Price Structure\nReference close $5.06 on 2026-08-14; RSI(14) 69.3; 52-week high $9.26, so -45.4%; 3-month return -1.9%. The relevant structure is the July shelf: $5.11 on July 10 → $4.48 on July 21 → $4.32 on July 24, then a recovery leg that carried price back above the July 10 level by August 14. That shelf near $4.32 is the level the current leg is measured from.\n\nThe narrative is **maturing**. The attention event is behind it — ASCO June 1, 2026 — and the price response to it has already been fully round-tripped. What is still expanding is sell-side coverage (three initiations or target raises dated July 8, July 20 and August 6, 2026), which is why this is not yet saturated: mainstream coverage has not arrived, and the last new institutional voice is ten days old. What disqualifies accelerating is the absence of new clinical information; the story being underwritten is the same one presented on June 1.\n\nCrowding and positioning observables, stated without a verdict: RSI(14) at 69.3 puts the August 14 close at the extended end of its own 14-day range after a recovery from $4.32; the Q2 earnings event already cleared on August 5, so the next print is not a hazard inside the window; the company disclosed no ATM or financing activity in the Q2 release; no Form 4 or offering filings surfaced in the coverage feed over the last 30 days, which is an absence of filings rather than affirmative evidence of insider behaviour. Sell-side targets cluster $14–$30 against a $5.06 close — a coverage-versus-price dispersion that has now held for five weeks.\n\n## Catalyst Calendar (next 30 days)\n- **No dated company catalyst falls between 2026-08-16 and 2026-09-15.** Q2 results were released 2026-08-05; the next scheduled corporate event is the Q3 print.\n- ~2026-11-05 (est.) — Q3 2026 results. Q1 landed 2026-05-15 and Q2 landed 2026-08-05, so early November is the pattern. Resolves burn trajectory against the \"into 2029\" runway claim and any change in financing language.\n- ~2026-12-31 (est., 2H 2026 guidance) — first patient dosed in the atebimetinib + cemiplimab NSCLC Phase 2. Confirms the second indication is real rather than a slide.\n- ~2026-12-15 (est., Q4 2026 guidance) — preclinical combination data supporting the NSCLC program.\n- 2028-mid (company guidance) — MAPKeeper 301 topline including primary-endpoint OS. The binary.\n\n## What Would Change Our Mind\nThe structural break is the July shelf giving way: a weekly close below $4.30 would undo the base the August leg was built from and re-open the post-ASCO downtrend that ran from $5.11 on July 10 to $4.32 on July 24. Separately, an equity raise or an S-3/ATM prospectus filed into a period with no clinical news would contradict the \"runway into 2029\" statement made on August 5, 2026 and reprice the cash-covered-option framing directly.\n\nOn the clinical side, the frame breaks if MAPKeeper 301 enrollment stalls — clinicaltrials.gov site count stagnating below the 30-plus reported on August 5, or company language moving off mid-2028 topline at any quarterly update. A randomized failure at a RAS/MAPK-pathway competitor in pancreatic cancer would also compress the historical-control argument that carries this entire story.\n\nThe frame strengthens instead if price holds above the July shelf on a retest with the sell-side range intact, or if the NSCLC Phase 2 doses its first patient inside 2026 as guided, which puts a dated clinical readout on the calendar for late-2027 and shortens the information vacuum by roughly a year.\n\n## Correlation Notes\n- Rate-sensitive small-cap biotech beta: a pre-revenue name whose entire value is a 2028 cash flow discounts directly off long rates, and it will trade with XBI/IBB drawdowns regardless of atebimetinib news.\n- Pancreatic-cancer sentiment trades as a group. A randomized OS win or failure from any RAS/MAPK-directed competitor in pancreatic cancer moves the whole comp set, including names with no read-through to Deep Cyclic MEK inhibition.\n- Partner-linked: the NSCLC arm depends on Regeneron supplying cemiplimab. Any change in that collaboration is idiosyncratic to IMRX but originates outside it.\n- With 64.7M weighted-average shares (Q2 2026) and no revenue line, single headlines and single broker actions move the quote more than sector flow does — the August 6 HC Wainwright initiation sits inside the window that took price from $4.32 to $5.06.",
  "first_seen": "2026-07-10",
  "last_analyzed": "2026-08-16T15:17:27+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}